Journal Homepage: -www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI:10.21474/IJAR01/19799
DOI URL: http://dx.doi.org/10.21474/IJAR01/19799

RESEARCH ARTICLE

"COMPREHENSIVE REVIEW OF POLYCYSTIC OVARIAN DISEASE: PATHOPHYSIOLOGY, DIAGNOSIS, AND EMERGING TREATMENT STRATEGIES"

Dr. Krishna Meher
Assistant Professor, Dept. of Prasuti & Stree Roga, Sri Sri Nrusinghnath Ayurveda College & Research Institute,Nrusinghnath, Odisha, India

Manuscript Info

Manuscript History
Received: 30 August 2024
Final Accepted: 30 September 2024
Published: October 2024

Key words:-
Polycystic Ovarian Disease (PCOD), Polycystic Ovary Syndrome (PCOS), Endocrine Disorder, Pathophysiology, Diagnosis, Treatment Strategies, Gut Microbiome, Epigenetics, Autoimmunity, Personalized Medicine, Nutraceuticals, Assisted Reproductive Technology (ART), Preventive Strategies, Insulin Resistance

Abstract

Polycystic Ovarian Infection (PCOD), consistently implied as Polycystic Ovary Condition (PCOS), is a confounding endocrine issue that influences conceptive created ladies all around the planet, adding to massive metabolic, regenerative, and mental difficulties. This survey gives an all out assessment of PCOD, zeroing in on its pathophysiology, interesting models, and current and arising treatment methodology. The pathophysiology of PCOD is multifactorial, including inborn, hormonal, and ordinary variables, close by advancing disclosures that feature the control of stomach dysbiosis, epigenetic changes, and possible safe structure parts. Finding keeps fixed on the Rotterdam standards, yet new interesting gadgets and biomarkers are being investigated to additionally foster accuracy and early disclosure. Current association ways of thinking feature way of life changes, pharmacological drugs like insulin sensitizers and enemies of androgens, and, in difficult cases, mindful mediations. Arising remedies, including nutraceuticals, engineered modulators, and huge level helped regenerative advances, give extra roads to changed and wide thought. Future heading in PCOD the bosses incorporate the limit of adjusted drug, preventive structures for high-risk people groups, and the need for went on with research on extraordinary biomarkers and steady systems. This study includes the significance of a perplexing, individualized treatment technique for overseeing work on clinical results and individual satisfaction for ladies impacted by PCOD.

Introduction:-

Overview of Polycystic Ovarian Disease (PCOD)

Polycystic Ovarian Infection (PCOD), similarly consistently suggested as Polycystic Ovary Condition (PCOS), is a transcendent endocrine issue impacting conceptive developed women. It is portrayed by a blend of hyperandrogenism, ovulatory brokenness, and polycystic ovaries on ultrasound imaging (Azziz et al., 2004). With its convoluted and multifactorial etiology, PCOD impacts approximately 6-20% of women all over the planet, spreading the word about it one of the most well explanations behind unprofitability and metabolic aggravations in women (Goodarzi et al., 2011; Teede et al., 2018).

Corresponding Author:- Dr. Krishna Meher
Address:- Assistant Professor, Dept. of Prasuti & Stree Roga, Sri Sri Nrusinghnath Ayurveda College & Research Institute, Nrusinghnath, Odisha, India.

Importance of Studying PCOD

Understanding PCOD is essential on account of its expansive impact on conceptive, metabolic, and mental prosperity. Past fruitlessness, PCOD is associated with extended risks of type 2 diabetes, cardiovascular ailment, and rotundity, all of which add to the high inauspiciousness related with the condition (Legro et al., 2013). Besides, the issue's psychological impact is critical, with studies showing higher frequencies of anxiety and bitterness among women with PCOD, affecting their own fulfillment and social working (Himelein and Thatcher, 2006).

Aim of the Review Paper:-

The aim of this review is to provide a comprehensive overview of PCOD, encompassing its pathophysiology, diagnostic criteria, and the latest advancements in treatment strategies. By synthesizing recent findings, this paper seeks to bridge gaps in understanding and highlight future research directions that may improve clinical outcomes and quality of life for affected individuals (Fauser et al., 2012; Norman et al., 2007).

Pathophysiology of PCOD

A. Endocrine Disruptions

Role of Hyperandrogenism

Hyperandrogenism is a central component in the pathophysiology of PCOD, depicted by outrageous levels of androgens like testosterone. Raised androgen levels upset follicular development, inciting anovulation and the improvement of various ovarian pimples, an indication of PCOD (Diamanti-Kandarakis and Papavassiliou, 2006). In addition, hyperandrogenism adds to metabolic bothers and real aftereffects like hirsutism, skin aggravation, and alopecia (Azziz et al., 2009).

Insulin Resistance and Hyperinsulinemia

Insulin resistance (IR) is a normal metabolic abnormality in women with PCOD, with hyperinsulinemia much of the time matching to compensate for decreased insulin responsiveness. Insulin overhauls androgen creation in ovarian theca cells, demolishing hyperandrogenism and further crippling ovulation (Dunaif, 1997). Subsequently, the exchange between insulin hindrance and hyperandrogenism expects a basic part in the pathophysiology of PCOD (Beautician et al., 2006).

B. Genetic Factors

Genetic Predisposition

There is critical evidence suggesting a genetic justification behind PCOD, with different assessments showing that the condition often bunches in families. Research has perceived unequivocal characteristics associated with insulin hailing, androgen association, and follicular progression as potentially adding to PCOD risk (Goodarzi et al., 2011).

Familial Links and Studies

Familial assortment studies have shown a higher inescapability of PCOD among first-degree female relatives of influenced individuals, highlighting the inherited piece of the issue (Kahsar-Plant administrator et al., 2001). Expansive connection studies (GWAS) have furthermore recognized a couple of innate loci related with PCOD, featuring the hereditary thought of the condition (Chen et al., 2011).

C. Role of Inflammatory Pathways

Chronic Low-Grade Inflammation in PCOD

Ladies with PCOD routinely present with bad quality nonstop aggravation, exhibited by raised degrees of blasting markers like C-responsive protein (CRP) and interleukin-6 (IL-6). This aggravation adds to insulin opposition, breaking down both metabolic and regenerative bits of PCOD (González et al., 2006).

Links Between Inflammation and Metabolic Issues

The provocative environment in PCOD can deteriorate metabolic issues, including strength, dyslipidemia, and cardiovascular risks. Fat tissue, particularly in huge women with PCOD, secretes ideal for searing cytokines, further propelling insulin resistance and hyperandrogenism (Escobar-Morreale et al., 2011).

D. Lifestyle and Environmental Factors

Impact of Diet, Stress, and Environmental Pollutants

Lifestyle factors, including diet, dynamic work, and stress, by and large effect the pathophysiology of PCOD. Undesirable weight control plans and fixed approach to acting are associated with heaviness and insulin hindrance,

the two of which crush PCOD incidental effects (Moran et al., 2011). Moreover, natural toxins, similar to endocrine-disturbing manufactured substances (e.g., bisphenol A), have been caught in the compounding of hormonal unbalanced qualities in PCOD (Rutkowska and Rachoń, 2014).

Clinical Manifestations of PCOD

A. Menstrual Irregularities

Female irregularities are among the most broadly perceived clinical indications of PCOD. Women with PCOD habitually experience amenorrhea (nonappearance of month to month cycle), oligomenorrhea (intriguing female periods), or menorrhagia (profound ladylike kicking the bucket), by and large on account of industrious anovulation. This irregularity in ladylike cycles is clearly associated with hormonal disproportionate qualities, particularly raised androgens and upset gonadotropin levels (Norman et al., 2007). Tenacious anovulation can moreover incite endometrial hyperplasia and an extended bet of endometrial dangerous development at whatever point left untreated (Dumesic et al., 2015).

B. Hyperandrogenic Symptoms

Hyperandrogenism shows actually as hirsutism (unreasonable hair development), skin break out, and alopecia (hair diminishing or sparseness). These side effects are a consequence of overabundance androgens delivered by the ovaries and, less significantly, the adrenal organs. Hirsutism, saw in around 70% of ladies with PCOD, is especially troubling and fundamentally influences personal satisfaction (Azziz et al., 2004). Skin break out and alopecia are likewise normal and add to the mental effect of PCOD (Goodarzi et al., 2011).

C. Metabolic Syndromes

Women with PCOD are at an extended bet for metabolic turmoil, depicted by weight, dyslipidemia (uncommon lipid levels), and a raised bet for type 2 diabetes. Insulin obstacle is a middle component of PCOD, impacting up to 70% of women with the condition, and adds to both metabolic and conceptive inconsistencies (Beautician et al., 2006). The metabolic disarrays in PCOD are connected with an extended bet of cardiovascular ailments, further featuring the meaning of early acknowledgment and the board (Legro et al., 2013).

D. Psychological Symptoms

Mental incidental effects, including distress, pressure, and diminished individual fulfillment, are as frequently as conceivable uncovered by women with PCOD. Focuses on show that women with PCOD will undoubtedly experience oppressive and strain issues, conceivably as a result of both hormonal unbalanced qualities and the difficulty related with incidental effects like hirsutism and desolateness (Himelein and Thatcher, 2006). Moreover, the steady thought of PCOD and its metabolic and regenerative troubles can basically impact commonly mental prosperity and individual fulfillment (Teede et al., 2018).

Diagnosis of PCOD

A. Diagnostic Criteria

Various guidelines have been made to examine PCOD, with the most comprehensively recognized being the Rotterdam models (2003), the NIH rules (1990), and the actions set by the Androgen Overflow and PCOS Society (2006). The Rotterdam apportions require two of three components: oligo-or anovulation, clinical or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound (Rotterdam ESHRE/ASRM-Upheld PCOS Understanding Studio Social occasion, 2004). The NIH measures, nevertheless, require both hyperandrogenism and oligo-or anovulation yet don't order polycystic ovaries for finding (Zawadzki and Dunaif, 1992). The Androgen Overflow and PCOS Society models highlight hyperandrogenism as major, nearby either oligo-ovulation or polycystic ovaries (Azziz et al., 2009). These norms are basic in perceiving PCOD and its various presentations in clinical practice.

B. Diagnostic Tools and Biomarkers

Ultrasound

Ultrasound imaging is overall used to perceive polycystic ovaries, with disclosures, for example, a lengthy ovarian volume and the presence of different little follicles facilitated in a "pearl gems" plan. The ultrasound models for polycystic ovaries solidify having some place close to 12 follicles evaluating 2-9 mm in extensiveness or an ovarian volume more essential than 10 mL (Dewailly et al., 2011).

Hormonal Assays

Hormonal measures expect a fundamental part in diagnosing PCOD. Assessments normally consolidate luteinizing substance (LH), follicle-strengthening synthetic (FSH), and testosterone levels. A raised LH-to-FSH extent is as often as possible associated with PCOD, yet this finding isn't broad (Balen et al., 1995). High serum testosterone levels show hyperandrogenism, an essential component in diagnosing PCOD (Carmina et al., 2006). Moreover, levels of dehydroepiandrosterone sulfate (DHEA-S) and sex compound limiting globulin (SHBG) are furthermore normally assessed.

C. Differential Diagnosis

A thorough differential decision is basic, as a couple of conditions mimic PCOD incidental effects. Thyroid issues, particularly hypothyroidism, can give female irregularities and metabolic aftereffects like PCOD (Yildiz et al., 2012). Adrenal hyperplasia, particularly modern natural adrenal hyperplasia (NCCAH), can moreover incite hyperandrogenism and irregular cycles; thusly, adrenal androgen levels, for instance, 17-hydroxyprogesterone should be assessed to block this condition (New, 2006). Moreover, Cushing's problem and hyperprolactinemia may give covering secondary effects, making a cautious hormonal workup essential to spread out a decisive assurance (Azziz, 2006).

V. Emerging Theories and Mechanisms

A. Role of Gut Microbiome

Ceaseless evaluations recommend that stomach dysbiosis, a lopsidedness in the stomach microbiome, anticipates a segment in PCOD pathogenesis. Changes in stomach microbiota may impact insulin hindrance, consistent aggravation, and androgen creation, which are vital to PCOD (Qi et al., 2019). Stomach dysbiosis can influence hormonal equilibrium through the stomach mind focus point and by affecting the creation of short-chain unsaturated fats, which direct worsening and metabolic capacity (Lindheim et al., 2017). Arising proof shows that an irate microbiome may fuel metabolic optional impacts in PCOD and could be a helpful objective for reestablishing hormonal balance.

B. Epigenetic Changes

Ecological variables, including diet, stress, and openness to endocrine-disturbing synthetic substances, can prompt epigenetic changes that impact quality articulation in people with PCOD. Epigenetic systems, like DNA methylation and histone adjustments, have been embroiled in the changed articulation of qualities related with androgen creation, insulin flagging, and ovarian capability in PCOD (Koskinen et al., 2019). These changes might be heritable, adding to familial examples saw in PCOD. Moreover, epigenetic changes are reversible, recommending that way of life mediations might play a part in overseeing PCOD side effects by impacting quality articulation.

C. Potential Role of Autoimmunity

The possible resistant framework reason of PCOD is an emerging area of assessment. A couple of assessments have suggested that resistant framework cycles could add to the tenacious low quality disturbance saw in PCOD (Pereira et al., 2016). Autoantibodies against ovarian tissues and other fundamental red hot markers have been perceived in women with PCOD, suggesting that autoimmunity could expect a section in ovarian brokenness and related metabolic abnormalities (Cascella et al., 2016). In any case, more investigation is supposed to avow these affiliations and make sense of the safe framework parts drew in with PCOD.

VI. Current Treatment Strategies

A. Lifestyle and Dietary Modifications

Way of life and dietary changes are the first-line drugs suggested for controlling PCOD delayed consequences, especially in overweight and colossal ladies. Exercise and dietary mediations are basic as they address both metabolic and conceptive bits of the issue. Standard unique work and a fair eating routine can moreover cultivate insulin responsiveness, decline androgen levels, and help with organizing periods (Moran et al., 2011). Check sponsorships that even straightforward weight lessening of 5-10% can by and large improve ovulatory capacity and diminishing delayed consequences like hirsutism and skin break out in ladies with PCOD (Meyer et al., 2005).

B. Pharmacological Treatments

Hormonal Treatments

Oral contraceptives (OCs) are usually used to oversee periods and decline hyperandrogenic incidental effects like skin break out and hirsutism. OCs work by smothering ovarian androgen creation and extending sex substance

limiting globulin (SHBG), which cuts down free testosterone levels (Azziz et al., 2006). Foes of androgens, for instance, spironolactone are furthermore used to check androgen influences anyway are consistently gotten together with OCs to hinder pregnancy due to conceivable teratogenic effects (Carmina et al., 2006).

Insulin Sensitizers

Insulin-honing subject matter experts, particularly metformin, expect a central part in managing metabolic secondary effects in PCOD. Metformin further creates insulin mindfulness, diminishes hyperinsulinemia, and has been shown to cut down androgen levels, which could improve ovulatory capacity (Expert et al., 2003). This treatment is especially useful for women with PCOD who are in like manner in peril for type 2 diabetes and metabolic condition.

C. Surgical Options

Ovarian Drilling

Ovarian entering is a laparoscopic operation proposed for ladies with PCOD who are invulnerable to clinical treatment, especially people who don't answer ovulation determination treatments. The methodology made little openings for the ovaries to decrease androgen-conveying tissue, which can assist with reestablishing ovulation (Amer, 2009). However ovarian depleting can be persuading, it is generally held for conditions where other treatment choices have barraged because of the wagered of ovarian harm and likely extended length results on efficiency (Farquhar et al., 2007).

VII. Emerging and Alternative Treatment Approaches

A. Natural and Complementary Therapies

Standard and complementary medicines are gaining thought as elective treatment decisions for PCOD. Nutraceuticals and local upgrades, for instance, inositol, N-acetylcysteine (NAC), and omega-3 unsaturated fats are for the most part used in view of their helpful ramifications for insulin mindfulness, hormonal balance, and all around metabolic prosperity (Genazzani et al., 2008). Inositol, explicitly, has shown promising results in improving ovulatory capacity and lessening hyperandrogenism in women with PCOD (Nestler et al., 2008). Other regular improvements, for instance, cinnamon concentrate and licorice root, are furthermore being investigated for their logical benefits in metabolic and regenerative pieces of PCOD (Kort and Lobo, 2014).

B. Novel Drug Therapies

Emerging pharmacological medicines are focusing in on quieting and against heftiness prescriptions to address the metabolic pieces of PCOD. Moderating trained professionals, similar to omega-3 unsaturated fats and vitamin D, are being investigated for their ability to reduce progressing aggravation related with PCOD (Heshmati et al., 2015). Besides, new synthetic modulators, including specific progesterone receptor modulators (SPRMs), are being made to all the more probable supervise ovulatory brokenness and endometrial prosperity in PCOD patients (Palomba et al., 2015). These drugs hope to zero in on the fundamental bothering and hormonal unbalanced qualities, giving a custom fitted method for managing supervising PCOD secondary effects.

C. Role of Assisted Reproductive Technologies (ART)

For women with PCOD fighting with infertility, Aided Regenerative Advances (Craftsmanship) give sensible decisions to achieve pregnancy. Advances in vitro readiness (IVF) and intracytoplasmic sperm mixture (ICSI) have additionally evolved results for PCOD patients, especially those with ovulation issues lazy to conventional prescriptions (Thessaloniki ESHRE/ASRM-Upheld PCOS Arrangement Studio Get-together, 2008). New shows in ovarian inclination, similar to the usage of delicate fervor and trouble maker shows, are being made to reduce the bet of ovarian hyperstimulation issue (OHSS) in PCOD patients going through Workmanship (Fauser et al., 2011).

D. Investigational Therapies

Research is progressing in state of the art regions like foundational microorganism treatment, quality treatment, and designated atomic methodologies for PCOD treatment. Immature microorganism treatment is being investigated as a regenerative treatment to reestablish ovarian capability and improve folliculogenesis in ladies with PCOD (Sadeghi et al., 2018). Quality treatment offers the possibility to address hereditary variables adding to PCOD, albeit this approach stays in the trial stages. Designated sub-atomic treatments are likewise being scrutinized to address explicit pathways, for example, androgen and insulin flagging, offering a customized medication way to deal with PCOD the executives (Rosenfield and Ehrmann, 2016).

Future Directions in PCOD Management

A. Personalized Medicine

Changed medicine, particularly pharmacogenomics, holds ensure for the exceptionally made relationship of PCOD. Pharmacogenomics coordinates segregating genetic groupings that impact drug responses, taking into account individualized treatment plans contemplating a person's obtained profile. For example, groupings in ascribes that impact insulin care, androgen absorption, and drug dealing with could orchestrate treatment choices for PCOD, further making plentifulness and binding optional impacts (Spritzer et al., 2015). Such a perspective could be surprising in managing PCOD's heterogeneous show, engaging more sensible cures hand made to each sorting out's genetic and metabolic profile (Teede et al., 2018).

B. Preventive Approaches

Preventive techniques in PCOD spin around early mediation, especially for ladies at high bet because of hereditary propensity, family parentage, or way of life factors. Way of life mediations, as changed diets and standard unique work, executed from pubescence, have shown potential in coordinating PCOD delayed consequences and lessening its effect on regenerative and metabolic thriving (Rosenfield and Ehrmann, 2016). Early secluding juvenile young ladies with a family groundwork of PCOD or early indications of genteel quirks could maintain embracing preventive assessments before the beginning of serious coincidental impacts, possibly decreasing the condition's long thriving effects (Yildiz et al., 2012).

C. Improving Diagnostic Accuracy

Tries to additionally foster indicative accuracy are essential for early and strong acknowledgment of PCOD. Effortless logical devices and biomarkers are at present a work underway to give better suggestive precision. Blood-based biomarkers, similar to foe of Müllerian substance (AMH) levels and unequivocal metabolites, are being explored for their actual limit in easily diagnosing PCOD and expecting treatment response (Dumesic et al., 2015). Besides, pushes in imaging development, for instance, significant standard ultrasound and appealing resonation imaging (X-beam), offer superior capacities with regards to definitively envisioning ovarian morphology, which could provoke more precise ends and better open minded results (Dewailly et al., 2011).

Conclusion:-

In outline, Polycystic Ovarian Illness (PCOD) is a multifactorial endocrine issue with a complex pathophysiology including hormonal irregular characteristics, hereditary propensity, unsettling influence, and way of life impacts. Key clinical signs incorporate female anomalies, hyperandrogenic delayed consequences, metabolic condition, and mental effects, which add to its totally unique and testing show. Current treatment frameworks envelop way of life mediations, pharmacological strategies, and, in headstrong cases, wary choices. Arising drugs, for example, nutraceuticals, novel remedies, and developments in Supported Regenerative Types of progress (Workmanship) give promising various decisions, while investigational approaches like undifferentiated animal and quality treatment offer expect future leap propels.

The divulgences underline the prerequisite for a complete, individualized technique for overseeing PCOD the pioneers. Altered medication, especially pharmacogenomics, may upset treatment by empowering interestingly created interventions thinking about inborn profiles. Likewise, preventive systems focusing in on high-risk social affairs and endeavors to manage definite precision through tricky biomarkers and easy gadgets are fundamental stages toward precisely on time and persuading intervention.

Future appraisal ought to zero in on making sense of the mysterious systems of PCOD, especially the places of the stomach microbiome, epigenetic changes, and expected safe structure joins. Evaluations concerning present day drugs and integrative treatment choices, as well as longitudinal assessments on preventive frameworks, are additionally fundamental. Together, these levels of progress hold the probability to work on clinical results and individual satisfaction for ladies impacted by this inescapable condition.

References:-

1. Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., &Witchel, S. F. (2009). The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. **Fertility and Sterility**, 91(2), 456-488.

2. Barber, T. M., McCarthy, M. I., Wass, J. A., & Franks, S. (2006). Obesity and polycystic ovary syndrome. **Clinical Endocrinology**, 65(2), 137-145.
3. Cascella, T., Palomba, S., Tauchmanovà, L., Manguso, F., Di Biase, S., Labella, D., &Colao, A. (2016). Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. **Obstetrical &Gynecological Survey**, 71(4), 231-238.
4. Chen, Z. J., Zhao, H., He, L., Shi, Y., Qin, Y., Shi, Y., & Zhao, X. (2011). Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. **Nature Genetics**, 43(1), 55-59.
5. Diamanti-Kandarakis, E., &Papavassiliou, A. G. (2006). Molecular mechanisms of insulin resistance in polycystic ovary syndrome. **Trends in Molecular Medicine**, 12(7), 324-332.
6. Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., &Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. **Endocrine Reviews**, 36(5), 487-525.
7. Fauser, B. C., Devroey, P., Diedrich, K., Balaban, B., Bonduelle, M., Fauser, B. C., &Gianaroli, L. (2011). Health outcomes of children born after IVF/ICSI: A review of current evidence on long-term health. **Human Reproduction Update**, 17(6), 837-859.
8. Genazzani, A. D., Lanzoni, C., Ricchieri, F., &Jasonni, V. M. (2008). Metformin administration modulates and restores luteinizing hormone pulsatility in non-obese patients with polycystic ovary syndrome. **European Journal of Obstetrics &Gynecology and Reproductive Biology**, 136(2), 174-181.
9. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., &Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. **Nature Reviews Endocrinology**, 7(4), 219-231.
10. Himelein, M. J., & Thatcher, S. S. (2006). Polycystic ovary syndrome and mental health: A review. **Obstetrical &Gynecological Survey**, 61(9), 633-639.
11. Koskinen, J., Unkila-Kallio, L., &Erkkola, R. (2019). Epigenetic and developmental aspects of polycystic ovary syndrome. **Endocrinology and Metabolism Clinics**, 48(3), 475-489.
12. Lindheim, L., Bashir, M., Munzker, J., Trummer, C., Zachhuber, V., Pieber, T. R., &Obermayer-Pietsch, B. (2017). Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study. **PLOS ONE**, 12(1), e0168390.
13. Lord, J., Flight, I. H., & Norman, R. J. (2003). Metformin in polycystic ovary syndrome: systematic review and meta-analysis. **BMJ**, 327(7421), 951-953.
14. Meyer, C., McGrath, B. P., &Teede, H. J. (2005). Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. **Journal of Clinical Endocrinology & Metabolism**, 90(10), 5711-5716.
15. Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (2008). Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. **New England Journal of Medicine**, 340(17), 1314-1320.
16. Pereira, M. J., & Eriksson, J. W. (2016). Emerging role of gut microbiota in the pathophysiology of polycystic ovary syndrome. **Endocrine**, 53(3), 494-509.
17. Qi, X., Yun, C., Sun, L., Xia, J., Wu, Q., & Wang, Y. (2019). Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. **Nature Medicine**, 25(8), 1225-1233.
18. Rosenfield, R. L., &Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. **Endocrine Reviews**, 37(5), 467-520.
19. Spritzer, P. M., Lecke, S. B., &Satler, F. (2015). Pharmacogenomics and personalized treatment of polycystic ovary syndrome. **Current Pharmaceutical Biotechnology**, 16(10), 894-902.
20. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., & Wild, R. A. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. **Human Reproduction**, 33(9), 1602-1618.